Robertson Stephens Wealth Management LLC Acquires 971 Shares of Eli Lilly and Company (NYSE:LLY)

Robertson Stephens Wealth Management LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 30.6% during the 4th quarter, Holdings Channel reports. The fund owned 4,145 shares of the company’s stock after purchasing an additional 971 shares during the period. Robertson Stephens Wealth Management LLC’s holdings in Eli Lilly and Company were worth $2,416,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in LLY. Lipe & Dalton bought a new stake in Eli Lilly and Company during the fourth quarter valued at about $26,000. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company during the third quarter valued at about $27,000. Legacy Financial Group LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $35,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth approximately $36,000. Finally, Family CFO Inc bought a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $40,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

LLY traded down $10.61 during midday trading on Thursday, hitting $766.14. 862,251 shares of the company were exchanged, compared to its average volume of 3,040,392. The company’s 50 day simple moving average is $762.03 and its 200 day simple moving average is $669.96. The firm has a market capitalization of $727.96 billion, a price-to-earnings ratio of 113.06, a price-to-earnings-growth ratio of 1.58 and a beta of 0.37. Eli Lilly and Company has a 1-year low of $414.31 and a 1-year high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 59.28% and a net margin of 17.08%. The company’s revenue was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.62 earnings per share. As a group, sell-side analysts predict that Eli Lilly and Company will post 13.5 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on LLY shares. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. BMO Capital Markets increased their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday. Wells Fargo & Company raised their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Finally, Truist Financial upped their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a report on Wednesday. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.